My-Linh Nguyen1, Baldwin Toye2, Salmaan Kanji3, Rosemary Zvonar4. 1. BScPhm, ACPR, is with the Department of Pharmacy, The Ottawa Hospital, Ottawa, Ontario. 2. MD, FRCPC, is with the Divisions of Microbiology and Infectious Diseases, The Ottawa Hospital, and the Faculty of Medicine, University of Ottawa, Ottawa, Ontario. 3. PharmD, is with the Ottawa Hospital Research Institute, Ottawa, Ontario. 4. BScPhm, ACPR, FCSHP, is with the Department of Pharmacy, The Ottawa Hospital, Ottawa, Ontario.
Abstract
BACKGROUND: Antimicrobial resistance due to production of extended-spectrum ß-lactamases by Escherichia coli and Klebsiella species (ESBL-EK) is concerning. Previous studies have shown that bacteremia due to ESBL-producing organisms is associated with increases in length of stay and/or mortality rate. Rates of infection by ESBL-EK vary worldwide, and regional differences in the prevalence of risk factors are likely. Few Canadian studies assessing risk factors for ESBL-EK infections or the outcomes of empiric therapy have been published. OBJECTIVES: To determine risk factors for and patient outcomes associated with ESBL-EK bacteremia. The appropriateness of empiric antibiotic therapy and the effect of inappropriate empiric therapy on these outcomes were also examined. METHODS: In a retrospective, 1:1 case-control study conducted in a tertiary care hospital between 2005 and 2010, data for 40 patients with ESBL-EK bacteremia were compared with data for 40 patients who had non-ESBL-EK bacteremia. RESULTS: Of all variables tested, only antibiotic use within the previous 3 months was found to be an independent risk factor for acquisition of ESBL-EK bacteremia (odds ratio 5.2, 95% confidence interval 1.6-16.9). A greater proportion of patients with non-ESBL-EK bacteremia received appropriate empiric therapy (88% [35/40] versus 15% [6/40], p < 0.001). Time to appropriate therapy was longer for those with ESBL-EK bacteremia (2.42 days versus 0.17 day, p < 0.001). Patient outcomes, including length of stay in hospital, admission to the intensive care unit (ICU), length of stay in the ICU (if applicable), and in-hospital mortality were not affected by the presence of ESBL-EK or the appropriateness of empiric therapy. CONCLUSIONS: Previous antibiotic use was a significant, independent risk factor for acquiring ESBL-EK. Thus, prior antibiotic use is an important consideration in the selection of empiric antibiotic therapy and should increase the concern for resistant pathogens.
BACKGROUND: Antimicrobial resistance due to production of extended-spectrum ß-lactamases by Escherichia coli and Klebsiella species (ESBL-EK) is concerning. Previous studies have shown that bacteremia due to ESBL-producing organisms is associated with increases in length of stay and/or mortality rate. Rates of infection by ESBL-EK vary worldwide, and regional differences in the prevalence of risk factors are likely. Few Canadian studies assessing risk factors for ESBL-EK infections or the outcomes of empiric therapy have been published. OBJECTIVES: To determine risk factors for and patient outcomes associated with ESBL-EK bacteremia. The appropriateness of empiric antibiotic therapy and the effect of inappropriate empiric therapy on these outcomes were also examined. METHODS: In a retrospective, 1:1 case-control study conducted in a tertiary care hospital between 2005 and 2010, data for 40 patients with ESBL-EK bacteremia were compared with data for 40 patients who had non-ESBL-EK bacteremia. RESULTS: Of all variables tested, only antibiotic use within the previous 3 months was found to be an independent risk factor for acquisition of ESBL-EK bacteremia (odds ratio 5.2, 95% confidence interval 1.6-16.9). A greater proportion of patients with non-ESBL-EK bacteremia received appropriate empiric therapy (88% [35/40] versus 15% [6/40], p < 0.001). Time to appropriate therapy was longer for those with ESBL-EK bacteremia (2.42 days versus 0.17 day, p < 0.001). Patient outcomes, including length of stay in hospital, admission to the intensive care unit (ICU), length of stay in the ICU (if applicable), and in-hospital mortality were not affected by the presence of ESBL-EK or the appropriateness of empiric therapy. CONCLUSIONS: Previous antibiotic use was a significant, independent risk factor for acquiring ESBL-EK. Thus, prior antibiotic use is an important consideration in the selection of empiric antibiotic therapy and should increase the concern for resistant pathogens.
Authors: Andrew J Denisuik; Philippe R S Lagacé-Wiens; Johann D Pitout; Michael R Mulvey; Patricia J Simner; Franil Tailor; James A Karlowsky; Daryl J Hoban; Heather J Adam; George G Zhanel Journal: J Antimicrob Chemother Date: 2013-05 Impact factor: 5.790
Authors: Vikas P Chaubey; Johann Dd Pitout; Bruce Dalton; Terry Ross; Deirdre L Church; Daniel B Gregson; Kevin B Laupland Journal: BMC Res Notes Date: 2010-04-27
Authors: Katherine E Goodman; Justin Lessler; Sara E Cosgrove; Anthony D Harris; Ebbing Lautenbach; Jennifer H Han; Aaron M Milstone; Colin J Massey; Pranita D Tamma Journal: Clin Infect Dis Date: 2016-06-28 Impact factor: 9.079